Bristol Myers Squibb Presents Encouraging Data from Phase 1 Breakfree-1 Study of CD19 NEX-T™ CAR T Cell Therapy in Three Chronic Autoimmune Diseases at ACR Convergence 2025

Core Insights - Bristol-Myers Squibb (BMS) presented promising data from the Phase 1 Breakfree-1 study of CD19 NEX-T™ CAR T cell therapy targeting three chronic autoimmune diseases at the ACR conference [1] Group 1: Study Findings - The Phase 1 Breakfree-1 study demonstrated encouraging results for the CD19 NEX-T™ CAR T cell therapy in patients with chronic autoimmune diseases [1] - The therapy showed a favorable safety profile and potential efficacy, indicating a significant advancement in treatment options for these conditions [1] Group 2: Implications for the Industry - The positive data from the study may enhance BMS's position in the competitive landscape of CAR T cell therapies, particularly in the autoimmune disease sector [1] - This development could lead to increased interest and investment in CAR T cell therapies, potentially influencing market dynamics and future research directions [1]